Product Name: WNK1 (57-63) pT60
Product Number: PE-04BBN00
Size: 200 µg      Price:26.00
1 mg      $US53.00
Peptide Name: WNK1 (57-63) pT60

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the N-terminal portion of the protein kinase. T60 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: RRH-pT-MDK

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1022.07 Da

Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Storage Stability: stable

Scientific Background: Wnk1 (PRKWNK1) is a protein-serine/threonine kinase of the Other group and Wnk family. It is involved in electrolyte homeostasis, cell survival, cell signalling, and cell proliferation. It is activated by hypertonicity. The activation requires autophosphorylation of S382. Phosphorylation of S378 also promotes increased phosphotransferase activity. Wnk1 can activate sodium-coupled chloride cotransporters, and inhibit potassium-coupled chloride cotransporters. Proteins activated by Wnk1 include SCNN1A, SCNN1B, SCNN1D and SGK1 while an inhibited protein is Wnk4 (via phosphorylation of Wnk4 or an associated complex of a Wnk1 autoinhibitory domain bound to Wnk4). Wnk4 inhibition could modulate, via phosphorylation, a thiazide-sensitive NaCl cotransporter transporter (specifically SLC12A3). Wnk1 has also been proposed to modulate NEDD4L phosphorylation, and have an effect on actin cytoskeleton rearrangement. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.